首页> 外文期刊>Journal of pediatric ophthalmology and strabismus >Comparison of mydriatic regimens used in screening for retinopathy of prematurity in preterm infants with dark irides.
【24h】

Comparison of mydriatic regimens used in screening for retinopathy of prematurity in preterm infants with dark irides.

机译:比较用于筛查具有黑色虹膜的早产儿早产儿视网膜病变的散瞳方案。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To determine the mydriatic regimen that provides optimal dilation of the pupil with minimal systemic side effects for screening of retinopathy of prematurity. METHODS: This cross-sectional, randomized, double-masked clinical trial compared cyclopentolate 1% + phenylephrine 2.5%, tropicamide 1% + phenylephrine 2.5%, and a prepared combination of cyclopentolate 0.2% with phenylephrine 1% for pupillary dilation in preterm infants with dark irides. Thirteen infants were randomized to each regimen. Outcomes measured were pupillary dilation, heart rate, blood pressure, abdominal girth, and intolerance to feeds. RESULTS: All three mydriatic regimens provided adequate pupillary dilation at 45 minutes, with dilation sustained at 60 minutes. There was a significant increase in mean blood pressure in the cyclopentolate 1% + phenylephrine 2.5% and the tropicamide 1% + phenylephrine 2.5% groups. Although there was no significant change of abdominal girth in any of the three groups, a total of eight patients developed intolerance to feeds; four (50%) of these infants were from the cyclopentolate 1% + phenylephrine 2.5% group. CONCLUSION: The prepared combination of cyclopentolate 0.2% + phenylephrine 1% appears to be the mydriatic of choice for preterm infants with dark irides as it provided adequate pupillary dilation with the least systemic side effects.
机译:目的:确定散瞳方案,以提供最佳的瞳孔扩张和最小的系统性副作用,以筛查早产儿视网膜病变。方法:这项横断面,随机,双掩盖的临床试验比较了早产儿低眼压婴儿的环戊酸酯1%+苯肾上腺素2.5%,托吡卡胺1%+苯肾上腺素2.5%,以及环戊酸酯0.2%和去氧肾上腺素1%的组合制备方法。黑暗的虹彩。每种方案随机分配13名婴儿。测量的结果是瞳孔扩张,心率,血压,腹围和对饲料的不耐受。结果:所有三种散瞳方案在45分钟时均提供足够的瞳孔扩张,并在60分钟时持续扩张。环戊酸酯1%+苯肾上腺素2.5%和托吡卡胺1%+苯肾上腺素2.5%组的平均血压显着增加。尽管三组的腹围均无明显变化,但共有八名患者对饲料不耐受。这些婴儿中有四(50%)来自环戊酸酯1%+苯肾上腺素2.5%组。结论:制备的0.2%环戊酸酯+ 1%苯肾上腺素的组合似乎是早产儿黑ir病的散瞳选择,因为它提供了足够的瞳孔扩张,而系统性副作用最小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号